These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 8070508)

  • 1. Cyclosporin pharmacokinetics in heart-lung transplant recipients with cystic fibrosis. Effects of pancreatic enzymes and ranitidine.
    Tsang VT; Johnston A; Heritier F; Leaver N; Hodson ME; Yacoub M
    Eur J Clin Pharmacol; 1994; 46(3):261-5. PubMed ID: 8070508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients.
    Rosenbaum SE; Baheti G; Trull AK; Akhlaghi F
    Ther Drug Monit; 2005 Apr; 27(2):116-22. PubMed ID: 15795639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclosporine pharmacokinetics and dose monitoring after lung transplantation: comparison between cystic fibrosis and other conditions.
    Knoop C; Vervier I; Thiry P; De Backer M; Kovarik JM; Rousseau A; Marquet P; Estenne M
    Transplantation; 2003 Aug; 76(4):683-8. PubMed ID: 12973109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of cyclosporine in heart and lung transplant candidates and recipients with cystic fibrosis and Eisenmenger's syndrome.
    Tan KK; Trull AK; Hue KL; Best NG; Wallwork J; Higenbottam TW
    Clin Pharmacol Ther; 1993 May; 53(5):544-54. PubMed ID: 8491066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian forecasting of oral cyclosporin pharmacokinetics in stable lung transplant recipients with and without cystic fibrosis.
    Rousseau A; Monchaud C; Debord J; Vervier I; Estenne M; Thiry P; Marquet P
    Ther Drug Monit; 2003 Feb; 25(1):28-35. PubMed ID: 12548141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAD in stable lung and heart/lung transplant recipients: safety, tolerability, pharmacokinetics, and impact of cystic fibrosis.
    Doyle RL; Hertz MI; Dunitz JM; Loyd JE; Stecenko AA; Wong RL; Chappell KA; Brazelton T; Kovarik JM; Appeldingemanse S; Dou L; Smith HT; Tudor D; Morris RE
    J Heart Lung Transplant; 2001 Mar; 20(3):330-9. PubMed ID: 11257560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered pharmacokinetics of cyclosporin in heart-lung transplant recipients with cystic fibrosis.
    Tan KK; Hue KL; Strickland SE; Trull AK; Smyth RL; Scott JP; Kelman AW; Whiting B; Higenbottam TW; Wallwork J
    Ther Drug Monit; 1990 Nov; 12(6):520-4. PubMed ID: 2274997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sandimmun neoral improves the bioavailability of cyclosporin A and decreases inter-individual variations in patients affected with cystic fibrosis.
    Girault D; Haloun A; Viard L; Bellon G; Gottrand F; Guillemain R; Lenoir G; Ladurie FL; Plouvier E; Storni V
    Transplant Proc; 1995 Aug; 27(4):2488-90. PubMed ID: 7652899
    [No Abstract]   [Full Text] [Related]  

  • 9. Assessment of converting from intravenous to oral administration of cyclosporin A in pediatric allogeneic hematopoietic stem cell transplant recipients.
    Choi JS; Lee SH; Chung SJ; Yoo KH; Sung KW; Koo HH
    Bone Marrow Transplant; 2006 Jul; 38(1):29-35. PubMed ID: 16715103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of two oral cyclosporin a formulations in clinically stable heart-transplant patients.
    Baraldo M; Pea F; Poz D; Furlanut M
    Pharmacol Res; 2001 Jun; 43(6):547-51. PubMed ID: 11419964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Converting cyclosporine A from intravenous to oral administration in hematopoietic stem cell transplant recipients and the role of azole antifungals.
    Atiq F; Hameli E; Broers AEC; Doorduijn JK; Van Gelder T; Andrews LM; Koch BCP; Versmissen J; de Winter BCM
    Eur J Clin Pharmacol; 2018 Jun; 74(6):767-773. PubMed ID: 29500599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absorption characteristics of a microemulsion formulation of cyclosporine in de novo pediatric liver transplant recipients.
    Dunn SP; Cooney GF; Kulinsky A; Falkenstein K; Pierson A; Elder CA; Meligeni J
    Transplantation; 1995 Dec; 60(12):1438-42. PubMed ID: 8545871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclosporin pharmacokinetics in paediatric transplant recipients.
    Cooney GF; Habucky K; Hoppu K
    Clin Pharmacokinet; 1997 Jun; 32(6):481-95. PubMed ID: 9195117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High intra-individual variability of cyclosporine pharmacokinetics in lung transplant recipients without cystic fibrosis.
    Méndez A; Monforte V; Berastegui C; López-Meseguer M; Bravo C; Pou L; Roman A
    Clin Transplant; 2014 Jun; 28(6):743-8. PubMed ID: 24708188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of an oral solution of the microemulsion formulation of cyclosporine in maintenance pediatric liver transplant recipients.
    Dunn S; Cooney G; Sommerauer J; Lindsay C; McDiarmid S; Wong RL; Chang CT; Smith HT; Choc MG
    Transplantation; 1997 Jun; 63(12):1762-7. PubMed ID: 9210501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative bioavailability of cyclosporin from conventional and microemulsion formulations in heart-lung transplant candidates with cystic fibrosis.
    Tan KK; Trull AK; Uttridge JA; Wallwork J
    Eur J Clin Pharmacol; 1995; 48(3-4):285-9. PubMed ID: 7589056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients.
    Schädeli F; Marti HP; Frey FJ; Uehlinger DE
    Clin Pharmacokinet; 2002; 41(1):59-69. PubMed ID: 11825097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An investigation of the pharmacokinetics, toxicity, and clinical efficacy of Neoral cyclosporin in cystic fibrosis patients.
    Mikhail G; Eadon H; Leaver N; Rogers P; Stephens D; Banner N; Khaghani A; Yacoub M
    Transplant Proc; 1997; 29(1-2):599-601. PubMed ID: 9123148
    [No Abstract]   [Full Text] [Related]  

  • 19. The pharmacokinetics of oral ranitidine in children and adolescents with cystic fibrosis.
    James LP; Stowe CD; Farrar HC; Menendez AA; Argao EA
    J Clin Pharmacol; 1999 Dec; 39(12):1242-7. PubMed ID: 10586389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis.
    Stuckey L; Clark Ojo T; Park JM; Annesley T; Bartos C; Cibrik DM
    Ther Drug Monit; 2014 Apr; 36(2):148-51. PubMed ID: 24232127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.